[
Afdhal, N., Zeuzem, S., Kwo, P., Chojkier, M., Gitlin, N., Puoti, M., Romero-Gomez, M., Zarski, J.-P., Agarwal, K., Buggisch, P., et al. (2014). Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Engl. J. Med., 370, 1889–1898.10.1056/NEJMoa1402454
]Search in Google Scholar
[
Balistreri, W. F., Murray, K. F., Rosenthal, P., Bansal, S., Lin, C.-H., Kersey, K., Massetto, B., Zhu, Y., Kanwar, B., German, P., et al. (2017). The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology, 66, 371–378.10.1002/hep.28995
]Search in Google Scholar
[
Bonacini, M., Kim, Y., Pitney, C., McKoin, L., Tran, M., Landis, C. (2020). Wirelessly observed therapy to optimize adherence and target interventions for oral hepatitis C treatment: Observational pilot study. J. Med. Internet Res., 22 (2), e15532. doi: 10.2196/15532.10.2196/15532
]Search in Google Scholar
[
Chugh, Y., Dhiman, R. K., Premkumar, M., Prinja, S., Grover, G. S., Pahuguna, P. (2019). Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. PLoS One, 14 (8), e0221769. doi: 10.1371/journal.pone.0221769.10.1371/journal.pone.0221769
]Search in Google Scholar
[
EASL (2020). EASL Policy Statement on Hepatitis C Elimination. https://easl.eu/wp-content/uploads/2019/04/EASL-Policy-Statement-on-Hepatitis-C-Elimination.pdf (accessed 22 November 2020).
]Search in Google Scholar
[
European Union HCV Collaborators (2017). Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: A modelling study. Lancet Gastroenterol Hepatol., 2, 325–336.
]Search in Google Scholar
[
Forns, X., Lee, S. S., Valdes, J., Lens, S., Ghalib, R., Aguilar, H., Felizarta, F., Hassainen, T., Hinrichsen, H., Rincon, D., et al. (2017). Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): A single-arm, open-label, multicentre phase 3 trial. Lancet Infect. Dis., 17, 1062–1068.10.1016/S1473-3099(17)30496-6
]Search in Google Scholar
[
Houghton, M. (2009). Discovery of the hepatitis C virus. Liver Int., 29 Suppl 1, 82–88. doi: 10.1111/j.1478-3231.2008.01925.x. PMID: 19207970.10.1111/j.1478-3231.2008.01925.x19207970
]Search in Google Scholar
[
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., Wedemeyer, H. (2018). EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol., 69 (2), 461–511. doi: 10.1016/j.jhep.2018.03.026.10.1016/j.jhep.2018.03.02629650333
]Search in Google Scholar
[
Polaris Observatory HCV Collaborators (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol. Hepatol., 2, 161–176.
]Search in Google Scholar
[
Stasi, C., Silvestri, C., Voller, F. (2020). Update on hepatitis C epidemiology: Unaware and untreated infected population could be the key to elimination. SN Compr. Clin. Med., 18, 1–8. doi: 10.1007/s42399-020-00588-3.10.1007/s42399-020-00588-3756868933103061
]Search in Google Scholar
[
Tolmane, I., Rozentale, B., Keiss, J., Arsa, F., Brigis, G., Zvaigzne, A. (2011). The prevalence of viral hepatitis C in Latvia: A population- based study. Medicina (Kaunas), 47 (10), 532–535.10.3390/medicina47100076
]Search in Google Scholar
[
Waheed, Y., Siddiq, M., Jamil, Z., Najmi, M. H. (2018). Hepatitis elimination by 2030: Progress and challenges. World J. Gastroenterol., 24 (44), 4959–4961. https://doi.org/10.3748/wjg.v24.i44.4959 (accessed 12.03.2022).10.3748/wjg.v24.i44.4959626225430510370
]Search in Google Scholar
[
Wirth, S., Rosenthal, P., Gonzalez-Peralta, R. P., Jonas, M. M., Balistreri, W. F., Lin, C.-H., Hardikar, W., Kersey, K., Massetto, B., Kanwar, B., et al. (2017). Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology, 66,1102–1110.10.1002/hep.2927828543053
]Search in Google Scholar
[
World Health Organization. Global Hepatitis Report 2017. http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf;jsessionid=A1E5CF10018D99C7C1291A9BCA6F05A9?sequence=1 (accessed 12.03.2022).
]Search in Google Scholar
[
World Health Organization (2016). Draft global health sector strategies: Viral hepatitis 2016–2021. http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1 (accessed 12.03.2022).
]Search in Google Scholar
[
Zeuzem, S., Foster, G. R., Wang, S., Asatryan, A., Gane, E., Feld, J. J., Asselah, T., Bourličre, M., Ruane, P. J., Wedemeyer, H., et al. (2018). Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. New Engl. J. Med., 378, 354–369.10.1056/NEJMoa170241729365309
]Search in Google Scholar
